Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-03-19
1998-04-21
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 851, 435 691, 435 694, A61K 4700, A61K 31685, A61F 200
Patent
active
057417784
ABSTRACT:
Methods are provided for preventing or reducing N-methyl-D-aspartate (NMDA) receptor agonist-mediated neuronal cell death by administering a glial cell line-derived neurotrophic factor (GDNF) protein product.
REFERENCES:
patent: 4518584 (1985-05-01), Mark et al.
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5106627 (1992-04-01), Aebischer et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5272071 (1993-12-01), Chappel
Arenas et al. (1995), `GDNF Prevents Degeneration and Promotes the Phenotype of Brain Noradrenergic Neurons In Vivo`, Neuron 15:1465-1473.
Beal et al. (1991), `Chronic Quinolinic Acid Lesions in Rats Closely Resemble Huntington'Disease`, J. Neurosci 11(6):1649-1659.
Choi (1988), `Glutamate Neurotoxicity and Diseases of the Nervous System`, Neuron 1:623-634.
Greenamyre et al. (1985), `Alterations in L-Glutamate Binding in Alzheimer'and Huntington's Diseases`, Science 227:1496-1499.
Humpel et al. (1994), `Neurons of the Hippocampal Formation Express Glial Cell Line-Derived Neurotrophic Factor Messenger RNA in Response to Kainate-Induced Excitation`, Neurosci. 59(4):791-795.
Lin et al. (1993), `GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons`, Science 260:1130-1132.
Martin et al. (1987), `Biphasic effect of quinolinate on frog spinal, but not rat cortical, neurones: N-methyl-D-aspartate-like depolarisation and a novel type of hyperpolarisation`, Neurosci. Lett.. 75:175-180.
Martin et al. (1994), rhGDNF Prevents Kainic Acid Induced Seizures and the Associated Neuronal Cell Death, Soc. Neurosci. Abstr. 20:193.12.
Martin et al. (1995), `Potent inhibitory effects of glial derived neurotrophic factor against kainic acid mediated seizures in the rat`, Brain Res. 683:172-178.
Norman et al. (1991), `Differential Loss of Neurochemical Markers following Quinolinic Acid-Induced Lesions of Rat Striatum`, Exp. Neurology 114:132-135.
Perez-Navarro et al. (1994), Nerve Growth Factor and Basic Fibroblast Growth Factor Protect Cholinergic Neurons Against Quinolinic Acid Excitotoxicity in Rat Neostriatum, Eur. J. Neurosci. 6:706-711.
Portera-Cailliau et al. (1995), `Evidence for Apoptotic Cell Death in Huntington Disease and Excitotoxic Animal Models`, J. of Neuroscience 15(5):3775-3787.
Roberts et al. (1993), `Intrastriatal Injections of Quinolinic Acid or Kainic Acid: Differential Patterns of Cell Survival and the Effects of Data Analysis on Outcome`, Exp. Neurol. 124:274-282.
Schwarcz et al. (1991), `Quinolinic Acid and Kynurenic Acid in the Mammalian Brain`, Kynurenine and Serotonin Pathways (Plenum Press, New York) pp. 185-199.
Susel et al. (1991), `Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease`, Neuroscience Lett. 121:234-238.
Ho et al, Neuroreport, 6(10), pp. 1454-1458 (1995) (Abstract).
Lin et al., Science, vol. 260:1130-32 (1993).
Greenamyre et al., Science, vol. 227, pp. 1496-1499 (1985).
Martin David
Miller Gerald D.
Amgen Inc.
Curry Daniel R.
Levy Ron K.
Odre Steven M.
Touzeeau P. Lynn
LandOfFree
Method for treating Huntington's disease using glial cell line-d does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating Huntington's disease using glial cell line-d, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating Huntington's disease using glial cell line-d will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2057574